BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Pappas Picks Likely Heir, Prepares for More IPOs
News | 09. 29. 2009
As Art Pappas makes plans for his eventual retirement, he's counting on the recent stock-market rebound to help some of the promising young companies he backs gain favor on Wall Street.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.